Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 15/20 | 0.38 |
| ▸ | PGR | P06401 | 5/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 8/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1492596 | 1.00 | NR3C1 (0.38) | NR3C1PGRNR3C2CA1CA2 | |
| SCHEMBL1492610 | 0.78 | NR3C1 (0.44) | NR3C1PGRNR3C2CA1CA2 | |
| SCHEMBL1492544 | 0.76 | NR3C1 (0.51) | NR3C1PGRNR3C2 | |
| SCHEMBL5802318 | 0.76 | ALDH1A1 (0.36) | NR3C1PGRNR3C2CYP3A4 | |
| SCHEMBL1492584 | 0.74 | NR3C1 (0.48) | NR3C1PGRNR3C2 | |
| SCHEMBL1716140 | 0.73 | NR3C1 (0.50) | NR3C1PGRNR3C2 | |
| SCHEMBL1492577 | 0.73 | NR3C1 (0.50) | NR3C1PGRNR3C2 | |
| SCHEMBL292229 | 0.72 | NR3C1 (0.61) | NR3C1PGRNR3C2CYP3A4 | |
| SCHEMBL12170409 | 0.70 | CA1 (0.47) | CA1CA2CA5ACA9BACE1 | |
| SCHEMBL1492540 | 0.69 | NR3C1 (0.46) | NR3C1PGRNR3C2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268859-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| EP-2300472-B1 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325988-A1 | Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 187/4885NR3C2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.